AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06312319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial exercises
Description: The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.
Study NCT06312319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial exercises
Description: The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.
Study NCT05080556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
Study NCT04741490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: PD-1antibodies，200mg ivgtt Q3W
Study NCT04741490 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 45-55Gy/1.8～2.0Gy
Study NCT05108558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH administration
Description: Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
Study NCT05108558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control - Crossover to CCH
Description: Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
Study NCT05108558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX
Description: Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
Study NCT05108558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RestoreX
Description: Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
Study NCT04757545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HM-PRO
Description: The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients:~1. Worsening in symptoms results in a nurse-led telephone consultation within two days guided by the symptom management manual.~2. Minor changes in patient's symptom assessment result in a nurse-led telephone consultation within seven days using the symptom management manual.~3. Patients that are completely stable in the symptom assessment will receive an electronic answer via min-SP (electronic patient journal) regarding the results and a new appointment, including PRO-data prior to this.
Study NCT06440551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleSalud Healthy Eating- Physical Activity/Sedentary Behavior (HE-PA/SB)
Description: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud HE-PA/SB Class, after which they will attend one maintenance meeting per month for 4 months. Weekly, Day 1 (Healthy Eating \& PA-SB Class): Participants will receive a 50-min. healthy eating class. Physical Activity- Sedentary Behavior (PA-SB) Class: By discussing barriers and strategies to overcome barriers, this will help to increase self-efficacy. We will engage in Latino-centered moderate impact (increasing to vigorous) aerobics with Latino or salsa movements and music for 45-50 minutes. Aspects of kickboxing aerobics will be integrated. Goal: Exercise a minimum of 150-250 min./ week of moderate intensity. Weekly, Day 2: PA-SB identical PA-SB to Day 1. Maintenance (Months 5-8): Meetings once/ month for 70 min. for HE/PA-SB class, including 25 min. to discuss diet and PA-SB barriers. Goal: Exercise a minimum of 150-250 min./week.
Study NCT06440551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleSalud General Health Intervention
Description: Weekly: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud General Heath Class, after which they will attend one maintenance meeting per month for 4 months. Participants will meet and discuss general health topics (not diet or PA). Examples of the general health topics are: Back Pain, Muscle Strains, Alcohol Use, Stress \& Coping, Oral and Dental Health, Safety Tips, Emergency Preparedness. The content is relevant to Latinos, and information is focused on Latino men. Maintenance (Months 5-8): Participants will meet via telehealth once/ month for 70 min. to discuss general health topics. To enhance motivation to complete the study and assessments, this group will receive a copy of the TeleSalud HE-PA/SB intervention manual and related materials after the maintenance period ends.
Study NCT05064566 — intervention group
Intervention type: DEVICE
Intervention: caries assessment
Description: clinical visual examination (ICDAS II), digital io radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), and micro-CT images.
Study NCT06516276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile App M.I.O
Description: This mobile app provides patients with access to various resources and therapies focused on nutrition, exercise, and emotional well-being. The main objective is to measure the quality of life of the app users through validated questionnaires in a randomized health education study to evaluate whether a substantial improvement in their well-being is achieved.
Study NCT05434806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarlsberg cheese
Description: Daly oral intake
Study NCT06250218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Interactive Guidance (VIG)
Description: Video interaction guidance (VIG) is a video feedback intervention through which a guider helps a client to enhance communication within relationships. The client is guided to analyse and reflect on video clips of their own interactions.
Study NCT05251376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomethadone HCl
Description: One dose given orally on Day 8 of the study.
Study NCT05251376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Daily usual oral dose given on Day 1 and Day 2 of the study.
Study NCT05251376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
Study NCT05251376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: x-ray
Description: Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.
Study NCT05251376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood tests
Description: Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
Study NCT06327958 — intervention group
Intervention type: OTHER
Intervention: Cormack-Lehane (C&L)
Description: There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
Study NCT04099940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Avatar Therapy (VRAT)
Description: The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
Study NCT04099940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Avatar Therapy (VRAT)
Description: The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
Study NCT04099940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assertiveness Training Program (ATP)
Description: The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
Study NCT04099940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertiveness Training Program (ATP)
Description: The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
Study NCT05936190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Intravenous infusion rate of lidocaine is 2 mg/kg/min
Study NCT05936190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intravenous infusion rate of lidocaine is 1 mg/kg/min
Study NCT06474468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102；Adebrelimab；Cisplatin
Description: Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06338527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Lavender oil was used for aromatherapy intervention.
Study NCT06338527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No aromatherapy intervention was performed during the period of the study.
Study NCT05845398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-AUD
Description: DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
Study NCT05845398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline for injection.
Study NCT05781698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
Study NCT05781698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
Study NCT05293158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatect CP 50 I.E./ml infusion solution
Description: Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection.
Study NCT05400772 — intervention group
Intervention type: OTHER
Intervention: electromyographic device
Description: An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
Study NCT06327958 — intervention group
Intervention type: OTHER
Intervention: POGO score
Description: There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
Study NCT06229327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THERAPEUTICGAMES
Description: THERAPEUTICGAMES
Study NCT06399250 — intervention group
Intervention type: OTHER
Intervention: meal service
Description: We're not subjecting patients to an intervention, as we will evaluate the current in-hospital meal service. As the three channel food concept is standard of care, we're not subjecting patients to dietary or behavioral changes. We will compare the data to an historic control.
Study NCT04454242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory muscle trainig
Description: This exercise will be used to strengthen forced expiratory muscles.
Study NCT04454242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle trainig
Description: This exercise will be used to strengthen forced expiratory muscles.
Study NCT05222126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose
Description: The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.
Study NCT05222126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline
Description: The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
Study NCT06003530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hOMSC200
Description: Human Oral Mucosal Stem Cells
Study NCT06003530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Animal component-free, defined cryopreservation medium with 5% DMSO
Study NCT05407246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay005
Description: Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
Study NCT05407246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005
Description: Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
Study NCT05222126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose
Description: The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.
Study NCT05222126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline
Description: The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
Study NCT05495165 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic education for patients in nutrition
Description: Stakeholders give preventive therapeutic education recommandations in their specific expertize
Study NCT05186506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensatinib
Description: 225 mg administered once daily orally for two years.
Study NCT05186506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
Study NCT05691114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAESCs
Description: human Amniotic Epithelial Stem Cells
Study NCT06366360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality Intervention
Description: The immersive virtual reality rehabilitation protocol is an experimental protocol based on musical practice. This protocol will be based on the Piano Vision application, which allows several modes of music production: free or guided musical practice.
Study NCT06366360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: The conventional rehabilitation corresponds to the classically performed in the cognitive treatment of unilateral spatial neglect. It involves training visual scanning using barrage exercises, sequence identification, scene description, and pointing.
Study NCT04984382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized training on Helicobacter pylori eradication treatment
Description: Standardized training on Helicobacter pylori eradication treatment
Study NCT06442670 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalography
Description: Phase synchrony during the completion of the semantic memory task
Study NCT05327868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat Diet (LFD)
Description: Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
Study NCT05177367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential Variety
Description: 3 courses each consisting of a different food
Study NCT05177367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous Variety
Description: 3 courses each consisting of 3 foods
Study NCT05177367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Food
Description: 3 courses each consisting of the same food
Study NCT05177367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small portion
Description: Small meal portion size
Study NCT05177367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Portion
Description: Large meal portion size
Study NCT05327868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet (HFD)
Description: Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
Study NCT05417581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adipose surgery
Description: A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
Study NCT04766411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unresisted sprint training
Description: Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint
Study NCT04766411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted sprint training with load equal to 10% of body weight
Description: Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint
Study NCT04766411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted sprint training with load equal to 20% of body weight
Description: Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint
Study NCT05483556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.
Study NCT05483556 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
Study NCT04417231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP apheresis
Description: Selective CRP apheresis by use of the PentraSorb-CRP
Study NCT06202040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.
Description: The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.